Literature DB >> 7708407

Responsiveness of slowly conducting articular afferents to bradykinin: effects of an experimental arthritis.

Karl Melinger1, Matthias Pawlak, Karsten Schepelmann, Robert F Schmidt.   

Abstract

Bradykinin (BK), an important inflammatory mediator and potent algogenic substance, is supposed to contribute to the generation of arthritic hyperalgesia and pain. The present study was undertaken to examine if an experimental kaolin/carrageenan arthritis sensitizes articular afferents to BK in the cat's knee joint using two different approaches. First, the proportion of afferent units activated by BK was assessed in fully inflamed joints and compared with corresponding data of normal knee joints. BK (injected i.a. as a bolus close to the joint) at the dose of 2.6 micrograms activated 60% of the units of groups II-IV in the inflamed state, compared to 71% in normal joints. The proportions of low- and high-threshold afferents activated by BK were similar, but more spontaneously active units than units without ongoing activity responded to BK both in inflamed and normal knee joints. Second, the responsiveness of individual afferent units to BK was examined during the development of inflammation. Units not activated by BK remained unresponsive after inflammation. From 11 units activated by BK, 3 units lost their responsiveness and in 4 other units the response to BK was reduced within 2-6 h after the onset of inflammation. Only in 4 units was the BK response increased in the inflamed joint. It is concluded that desensitizing rather than sensitizing processes are involved to change the response behavior of articular afferents to BK during acute experimental inflammation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7708407     DOI: 10.1016/0304-3959(94)90019-1

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  3 in total

1.  Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor.

Authors:  Alyson Fox; Satbir Kaur; Bifang Li; Moh Panesar; Uma Saha; Clare Davis; Ilaria Dragoni; Sian Colley; Tim Ritchie; Stuart Bevan; Gillian Burgess; Peter McIntyre
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

2.  Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia.

Authors:  G M Burgess; M N Perkins; H P Rang; E A Campbell; M C Brown; P McIntyre; L Urban; E K Dziadulewicz; T J Ritchie; A Hallett; C R Snell; R Wrigglesworth; W Lee; C Davis; S B Phagoo; A J Davis; E Phillips; G S Drake; G A Hughes; A Dunstan; G C Bloomfield
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

Review 3.  Secreted Phospholipases A₂ from Animal Venoms in Pain and Analgesia.

Authors:  Vanessa O Zambelli; Gisele Picolo; Carlos A H Fernandes; Marcos R M Fontes; Yara Cury
Journal:  Toxins (Basel)       Date:  2017-12-19       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.